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Abstract Prostate and breast carcinomas are sex hormone-re-
lated carcinomas, which are known to be associated with an
over-expression of the proto-oncogene Bcl-2. Here, we report
that 2-methoxyestradiol (2-ME), an endogenous metabolite of
estrogen that does not bind to nuclear estrogen receptors, e¡ec-
tively induces apoptosis in Bcl-2-expressing human prostate and
breast carcinoma cells in vitro and in a rat prostate tumor model
in vivo. In several cell lines derived from prostate, breast, liver
and colorectal carcinomas, 2-ME treatment led to an activation
of c-Jun N-terminal kinase (JNK) and phosphorylation of Bcl-
2, which preceded the induction of apoptosis. In summary, our
data suggest that 2-ME induces apoptosis in epithelial carcino-
mas by causing phosphorylation of JNK, which appears to be
correlated with phosphorylation of Bcl-2.
) 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis has been recognized as an important regulator of
tumor development and net tumor growth is dependent on the
balance between proliferation and apoptosis [1]. Another cru-
cial regulator of tumor progression and metastasis is angio-
genesis, as described by Folkman and coworkers [2,3]. Hor-
mone-related breast and prostate carcinomas are common in
populations of the Western society and the incidences of both
diseases are rising [4,5]. The proto-oncogene Bcl-2 protects
cells from di¡erent forms of apoptotic stimuli by preventing
caspase activation [6,7]. It has been shown that hormone ther-
apy-resistant prostate tumor cells expresses Bcl-2, whereas
normal prostate cells are Bcl-2-negative [8,9]. Furthermore,
breast carcinomas commonly express Bcl-2 [10].
2-Methoxyestradiol (2-ME), an endogenous metabolite of
the endogenous estrogen hormone estradiol-17L, has been
shown to potently inhibit angiogenesis and tumor growth in
vivo [11]. The growth-inhibitory properties of 2-ME have
been associated with its e¡ects on tubulin polymerization,
causing an increased stability of microtubules, which probably
results in cell cycle arrest [11^13]. Endothelial cells treated
with 2-ME displayed morphological signs of apoptosis after
as early as 5 h which was associated with an activation of
stress-activated protein kinase (SAPK)/c-Jun N-terminal ki-
nase (JNK) [14]. 2-ME has recently been shown to cause
growth inhibition [15] and also apoptosis in human lung
and pancreatic cancer cells [16,17]. Interestingly, the apoptotic
e¡ects of 2-ME appears to be most e¡ective in rapidly grow-
ing cells, particularly tumor cells in vitro and in vivo,
although the underlying molecular mechanism is not yet rec-
ognized [18^22]. The antiproliferative and apoptotic e¡ects of
2-ME in human breast carcinoma cells and endothelial cells
have recently been demonstrated to occur independently of
the described estrogen receptors (K and L) [23]. The inhibitory
e¡ects on tumor growth and angiogenesis of 2-ME are in-
creasingly well recognized, but the physiological function for
2-ME remains to be determined.
Mitogen-activated protein kinases (MAPKs) transduce sig-
nals from the cell membrane to the nucleus in response to
di¡erent stimuli and participate in intracellular signaling path-
ways that control a wide spectrum of cellular processes, in-
cluding cell growth, di¡erentiation and stress responses [24^
26]. In contrast to p42 extracellular signal-regulated kinase
(ERK)2 and p44 ERK1, which are activated by mitogenic
stimuli, the JNK/SAPK and p38 MAPKs are activated by
pro-in£ammatory cytokines and environmental stress such
as UV light, Q-irradiation, heat shock, osmotic shock, shear
stress, growth factor withdrawal, ceramides and inhibition of
protein synthesis. Upon activation, SAPK/JNK can phos-
phorylate several transcription factors like c-Jun, ATF-2 and
Elk-1 thereby regulating gene expression [27^29]. It has been
shown that activation of JNK and p38 MAPKs promotes
apoptosis, e.g. upon growth factor withdrawal in rat PC12
cells [30]. Similar to the case for ERKs, activation of
SAPK/JNK requires phosphorylation at conserved threonine
and tyrosine residues, by SEK1/MKK4/JNK kinase [29,31].
G protein-coupled receptors (GPCRs) are integral membrane
proteins involved in the transmission of signals from the
extracellular environment to the cytoplasm, which recently
have been shown to regulate MAPK cascades, including
ERK, SAPK/JNK and the p38 MAPK pathways [32].
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We report here that 2-ME treatment induced apoptosis in
rapidly growing cells, like prostate and breast carcinoma cells.
Moreover, 2-ME treatment of rats transplanted with a spon-
taneous prostate tumor resulted in a reduction of the tumor
volume compared to vehicle-treated rats. The potent apopto-
tic e¡ects of 2-ME were found to be associated with activation
of JNK, causing subsequent phosphorylation and inactivation
of the proto-oncogene Bcl-2.
2. Materials and methods
2.1. Materials
2-ME, estradiol-17L, forskolin, curcumin and propidium iodide
were obtained from Sigma Chemical (St. Louis, MO, USA). Pertussis
toxin (Ptx) was obtained from Calbiochem (La Jolla, CA, USA) and
z-VAD-fmk was obtained from Enzyme Systems Products (Liver-
more, CA, USA).
2.2. Cell culture and reagents
The human prostate cancer cell lines PC-3, LNCaP and DU-145,
the breast cancer cell lines MCF-7 and MDA-MB-468, the human
colon carcinoma cell line SW-480 and the human hepatocarcinoma
cell line HepG2 were routinely grown in RPMI 1640 (PC-3, LNCaP
and DU-145), minimal essential medium (MCF-7) or Dulbecco’s min-
imal essential medium (DMEM; MDA-MB-468, SW-480, HepG2)
containing 10% fetal bovine serum (FBS), L-glutamine and penicillin
(Gibco BRL, Paisley, UK). At least 24 h before experimentation the
medium for MCF-7 was changed to EX-MEM, which does not con-
tain phenol red, supplemented with 10% FBS.
2.3. Primary cell culture
The mammary epithelial cell organoids were isolated from human
normal breast and the method for culturing organoids was modi¢ed
from an earlier publication [33,34]. Normal breast tissue was imme-
diately placed in cold phosphate-bu¡ered saline (PBS), minced into
pieces of about 1 mm3 and washed three times with PBS. The minced
tissues were incubated at 37‡C for 8^10 h in an enzymatic solution
containing 75% M199, 25% DMEM, 10% FBS, 10 Wg/ml insulin, 145
Wg/ml hyaluronidase and 0.6 Wg/ml collagenase (type I). Isolated cells
were collected by centrifugation at 300Ug for 10 min and resuspended
in medium I (75% DMEM, 25% Ham’s F12, 10% FBS, 5 Wg/ml in-
sulin, 5 Wg/ml T3, 5 Wg/ml adenine, 10 pg/ml epidermal growth factor
(EGF), 20 Wg/ml hydrocortisone and 50 Wg/ml gentamicin). After
1 week of culturing at 37‡C in 95% air, 5% CO2, medium I was
replaced by medium II (75% DMEM, 25% Ham’s F12, 10% FBS,
5 Wg/ml insulin, 10 pg/ml EGF, 20 Wg/ml hydrocortisone, 141 Wg/ml
phosphoethanolamine and 50 Wg/ml gentamicin). The viability of iso-
lated cells was greater than 85% as assessed by trypan blue dye ex-
clusion.
2.4. DNA fragmentation assay
DNA fragmentation analysis was performed on con£uent cells har-
vested from tissue culture dishes as well as on cells collected by cen-
trifugation of supernatants from con£uent cell cultures (1U106/ml),
treated with 10 WM 2-ME for di¡erent time periods as indicated in the
¢gures. The cell pellet was resuspended in 20 Wl of sterile 10 mM
EDTA, 50 mM Tris^HCl, pH 8.0, 0.5% (w/v) sodium lauryl sarcosi-
nate and 0.5 mg/ml proteinase K and incubated at 37‡C for 1 h.
RNase A (1 mg/ml) was added and the sample was incubated for
15 min at 65‡C. DNA was extracted using phenol^chloroform and
electrophoresed on a 1.2% agarose gel in the presence of 0.1 Wg/ml
ethidium bromide for 2^4 at 80 Vh. DNA was visualized by UV light
and gels were photographed.
2.5. In situ detection of apoptosis
The TUNEL (terminal deoxynucleotide transferase-mediated dUTP
nick-end labeling) method was performed according to the instruc-
tions supplied by the manufacturer (Roche Molecular Bioscience,
Mannheim, Germany). Cells were cultured on collagen I-coated cul-
ture slides (Biocoat, Becton Dickinson, Bedford, MA, USA). Para⁄n-
embedded, formalin-¢xed 4 Wm thick tumor sections were used for the
investigations of apoptotic cells by TUNEL, as described earlier [35].
2.6. FACS analysis
Cell cycle studies were done by £ow cytometry according the meth-
od described by Vindelo«v et al. [36]. Brie£y, 1^2U106 cells were in-
cubated with or without 2-ME; £oating and attached cells were then
collected and pooled, washed with cold PBS and lysed in a NP-40-
containing bu¡er [36]. After treatments with trypsin and RNase A,
nuclei were stained with propidium iodide and analyzed by £ow cy-
tometry (FACScan; Becton Dickinson, Mountain View, CA, USA).
Apoptotic cells were determined by their hypochromic, sub-G1, stain-
ing pro¢les.
2.7. In vivo experiments
Dunning R3327-PAP prostate tumors, originally provided by Dr.
N. Altman (The Papanicolaou Cancer Research Institute, Miami, FL,
USA), were transplanted bilaterally subcutaneously into the £anks of
CopenhagenUFisher F1 male rats. This tumor sub-line has been well
characterized and is androgen-sensitive [37]. Rats were housed under
standard conditions with food and water ad libitum. Four to ¢ve
months post-implantation, when the tumor volume was approxi-
mately 1200 mm3, the rats were allocated consecutively to treatment
with vehicle (¢ve rats with eight tumors; NaCl 0.2 ml given intra-
peritoneally daily for 14 days) or 2-ME (six rats with 11 tumors, 12.5
mg/kg/day, total volume 0.2 ml). 2-ME was dissolved in sterile sesame
oil at a concentration of 125 mg/ml. All animal experiments were done
with permission of the local ethical committee. Diameters of tumors
were measured by microcalipers and the tumor volume was calculated
as described earlier [38].
2.8. Western blot analysis
Cells grown on 10 cm dishes were treated with 10 WM 2-ME for
di¡erent time periods, washed with PBS and lysed in 100 Wl lysis
bu¡er (50 mM Tris^HCl, pH 8.0, 150 mM NaCl, 0.02% sodium azide,
1% NP-40, 100 Wg/ml phenylmethylsulfonyl £uoride, and 1 Wg/ml
aprotinin). After centrifugation, supernatants were collected and pro-
tein concentrations were measured by using the Bio-Rad Protein
Assay Kit. Equal amounts of protein were subjected to SDS^gel elec-
trophoresis in 10^12% polyacrylamide gels, and blotted onto polyvi-
nylidene di£uoride membranes. Membranes were probed with anti-
bodies against the following proteins: phosphorylated and total
SAPK/JNK, phosphorylated and total p38 (New England Biolab,
Beverly, MA, USA), phosphorylated and total ERK1/2 (a⁄nity-puri-
¢ed polyclonal antibodies, a kind gift of Dr. Lars Ro«nnstrand, Lud-
wig Institute for Cancer Research, Uppsala, Sweden), Bcl-2, caspase
1, 3 and 8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Signals
were detected by an enhanced chemoluminescent (ECL) system.
2.9. Statistics
Values are expressed as meansUS.E.M. For comparisons between
groups the Mann^Whitney U-test was used. A P value less than 0.05
was considered to be statistically signi¢cant.
3. Results
3.1. 2-ME induces apoptosis in breast and prostate carcinoma
cell lines but not in normal breast cells
To investigate the cellular e¡ects of the estradiol metabolite
2-ME, we incubated di¡erent cell lines with 2-ME and fol-
lowed cell survival. 2-ME treatment of two human breast
carcinoma cell lines, MCF-7 (estrogen receptor-K-positive)
and MDA-MB-468 (estrogen receptor-K-negative), as well as
two human prostate carcinoma cell lines, PC-3 and LNCaP,
potently induced apoptosis, as demonstrated by a DNA frag-
mentation assay (Fig. 1A). The kinetics of 2-ME-induced ap-
optosis were di¡erent in the investigated cell lines with a max-
imal e¡ect observed using 10 WM (data not shown). The most
rapid response was evident in MDA-MB-468 cells, in which
DNA fragmentation was already seen after 6 h of incubation
with 2-ME. DNA fragmentation occurred after 24 h of 2-ME
treatment in PC-3 cells, and after 36 h and 48 h in LNCaP
and MCF-7 cells, respectively. A TUNEL assay con¢rmed the
apoptotic e¡ect of 2-ME in all cell lines (Fig. 1B). FACS
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analysis was used to quantify the sub-G1 fraction of cells, as a
marker of the number of apoptotic cells. 2-ME increased the
sub-G1 portion of cells by time, to approximately 30% of
MDA-MB-468 (24 h), 40% of MCF-7 (72 h), and 35^40%
of PC-3 and LNCaP cells (48 h). Moreover, in PC-3 and
LNCaP cells, 2-ME induced apoptosis more e¡ectively than
treatment with estradiol (Fig. 1C). In contrast, 2-ME treat-
ment of normal breast cells did not induce apoptosis (Fig.
1D). We therefore conclude that 2-ME potently induces apo-
ptosis in prostate and breast carcinoma cells, although with
di¡erent kinetics.
3.2. 2-ME inhibits prostate tumor growth in vivo by the
induction of apoptosis of endothelial and tumor cells
To investigate the apoptotic e¡ect of 2-ME in vivo, Copen-
hagenUFisher F1 rats transplanted with the spontaneous
Dunning R3327-PAP rat prostate tumors received intraperi-
toneal injections of 2-ME (12.5 mg/kg/day) for 14 days. Under
these conditions 2-ME signi¢cantly reduced the relative tumor
growth to 67U 18% (n=11), compared to 149U 50% in the
control group (n=8, P6 0.05, Fig. 2A). The mean tumor
weight in the control group was 11.9 U 1.3 g (n=8) compared
to 6.1U 0.6 g in the 2-ME-treated group (n=11, P6 0.02). In
tumors from rats treated with 2-ME macroscopically ¢brotic
tissue was observed in their centers (Fig. 2B), implying that 2-
ME caused massive cell death in the tumor and/or endothelial
cells. This was further con¢rmed by TUNEL, clearly identify-
ing apoptotic tumor and endothelial cells (Fig. 2C). Rats tol-
erated at least 14 days of 2-ME treatment without visible signs
of side e¡ects (like hair loss, diarrhea, infection, lethargy or
severe weight loss). The average body weight, including tu-
mors, in the control group before treatment was 478U 10 g,
and 476U 9 g in the 2-ME group. At the end of the treatment
period the body weight, including tumors, was 448U 8 g in the
control group and 407U 12 g in the 2-ME-treated group. In
summary, 2-ME treatment inhibits growth of solid prostate
tumors in vivo, caused by induction of apoptosis of endothe-
lial and tumor cells. Importantly, no major toxic side e¡ects
were observed during 2-ME treatment of rats, except a mod-
erate loss of weight.
Fig. 1. 2-ME induces apoptosis in human prostate and breast carcinoma cell lines but not in normal primary breast cells. A: DNA was ex-
tracted from attached cells as well as from cells £oating in the medium of the human prostate (PC-3, LNCaP) and breast (MDA-MB-468,
MCF-7) carcinoma cell lines. The cells were treated with 10 WM 2-ME for indicated times in medium containing 10% FBS. DNA was electro-
phoresed in 1.2% agarose gel and visualized by UV light. B: The presence of apoptotic cells was identi¢ed by TUNEL assay according to the
manufacturer’s manual (Roche) in various cell lines treated or not with 10 WM 2-ME. PC-3 cells were treated for 24 h, LNCaP cells for 36 h,
MDA-MB-468 cells for 12 h and MCF-7 cells for 36 h, before ¢xation and processed for TUNEL staining to visualize apoptotic cells. C: Cells
were harvested at di¡erent time points after treatment with 10 WM 2-ME or estradiol-17L (E2), ¢xed, stained with propidium iodide and ana-
lyzed for DNA staining pro¢les by FACS analysis. The results from the FACS analysis in the di¡erent cell lines are shown in the ¢gures to
the left and were performed after 24 h, 72 h, 36 h and 48 h of treatment in MDA-MB-468, MCF-7, PC-3 and LNCaP cells, respectively. The
sub-G1 fraction is determined as the fraction in M1 and the percentage of sub-G1 cells in the di¡erent cell lines are shown in the panels to the
right. D: Normal primary breast cells and MDA-MB-468 cells were treated with 2-ME for indicated times in medium containing 10% FBS and
subjected to DNA fragmentation assay.
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3.3. 2-ME activation of SAPK/JNK results in
caspase-dependent apoptosis
Next we studied the molecular details of the cellular e¡ects
of 2-ME. Addition of 2-ME activated SAPK/JNK in the in-
vestigated tumor cell lines after 20^60 min of stimulation (Fig.
3A). The strongest induction of SAPK/JNK phosphorylation
was observed in MDA-MB-468 cells, in which also apoptosis
occurred most rapidly. In contrast, challenge of MDA-MB-
Fig. 1 (Continued).
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468 cells with 2-ME did not activate ERK1/2 (Fig. 3B) or
p38 (data not shown). Curcumin has been reported to inhibit
AP-1, NF-UB and SAPK/JNK activation, with the highest
sensitivity against SAPK/JNK activation induced by UV-C
or Q-irradiation [39]. Although curcumin is not a speci¢c in-
hibitor of SAPK/JNK activation, we used curcumin in the
present study since we found that curcumin inhibited in
a dose-dependent manner the 2-ME-induced activation of
SAPK/JNK in MDA-MB-468 cells (data not shown). Curcu-
min prevented the 2-ME-induced apoptosis in PC-3 (data not
shown) and MDA-MB-468 cells (Fig. 3C). As shown in Fig.
3D, simultaneous treatment with the general caspase inhibitor
z-VAD-fmk partially (MDA-MB-468 and LNCaP cells) or
totally (MCF-7 and PC-3 cells) inhibited the 2-ME-induced
apoptosis. Therefore, 2-ME activates SAPK/JNK in the inves-
tigated breast and prostate carcinoma cell lines, resulting in a
caspase-dependent apoptosis.
3.4. Inhibition of 2-ME-induced phosphorylation of SAPK/JNK
by simultaneous treatment with Ptx
Next we aimed to investigate which proteins could be up-
stream of SAPK/JNK in the 2-ME-induced apoptosis. Sur-
prisingly, the 2-ME-induced activation of SAPK/JNK was
inhibited in a dose-dependent manner by preincubation with
Ptx indicating an involvement of heterotrimeric Gi=o proteins
(Fig. 4A). Furthermore, Ptx also inhibited the 2-ME-induced
apoptosis in MDA-MB-468 cells (Fig. 4B). Activation of Gi is
known to reduce cellular levels of cAMP [40]. Interestingly,
application of forskolin, a G protein-independent activator of
adenylate cyclase, to MDA-MB-468 cells 30 min before treat-
ment with 2-ME rescued cells from undergoing apoptosis
(data not shown). Therefore, our data suggest that 2-ME
activates Gi=o proteins, leading to a modulation of cAMP,
activation of JNK and subsequent apoptosis in MDA-MB-
468 cells.
Fig. 2. 2-ME inhibits growth of a rat prostate tumor (Dunning R3327-PAP) in vivo, by induction of apoptosis in tumor and endothelial cells.
A: Intraperitoneal injections of 2-ME (12.5 mg/kg/day) for 14 days signi¢cantly (*P6 0.05) reduced the relative tumor growth in comparison
with rats treated with vehicle (0.2 ml NaCl, 9 mg/ml). B: Photographs of tumors grown in rats treated with vehicle or 2-ME. Macroscopically
¢brotic tissue was observed in the center of 2-ME-treated tumors (arrow), while vehicle-treated tumors were composed of macroscopically via-
ble cells. C: TUNEL assay performed on sections counterstained with hematoxylin from sections of tumors treated with vehicle or 2-ME. TU-
NEL-positive apoptotic tumor and endothelial cells were identi¢ed in 2-ME-treated tumors, indicated by arrows (tumor cells) and arrowheads
(endothelial cells). Blood vessels are indicated with V. 40U magni¢cation.
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3.5. Phosphorylation of Bcl-2 in prostate and breast carcinoma
cells is associated with 2-ME-induced apoptosis
Since Bcl-2 is a key component in regulation of cell survival
and apoptosis we wondered whether it is involved in the ob-
served apoptotic e¡ect of 2-ME. 2-ME treatment resulted in a
phosphorylation of Bcl-2 in prostate (PC-3, LNCaP) and
breast (MCF-7, MDA-MB-468) carcinoma cell lines (Fig.
5A). Kinetics of the 2-ME-induced phosphorylation of Bcl-
2, di¡ered in the investigated cell lines, but always preceded
the onset of apoptosis (see Fig. 1). To investigate whether the
phosphorylation of Bcl-2 is linked to the apoptotic e¡ect of 2-
ME, the human prostate carcinoma cell line DU-145 that
lacks Bcl-2 was studied (Fig. 5B). 2-ME treatment activated
SAPK/JNK, but did not induce apoptosis in DU-145 cells
(Fig. 5C), while challenge with 10 ng/ml transforming growth
factor-L1 (TGF-L1) was able to induce apoptosis, as shown by
DNA fragmentation analysis (Fig. 5D). In MDA-MB-468
cells, Ptx and curcumin could inhibit the 2-ME-induced phos-
phorylation of Bcl-2. Furthermore, the caspase inhibitor
z-VAD-fmk also prevented 2-ME-induced phosphorylation
of Bcl-2 in MDA-MB-468 cells (Fig. 5E). Taken together,
our data show that the 2-ME-induced phosphorylation of
Bcl-2 is prevented by Ptx, curcumin and a caspase inhibitor,
treatments which also inhibited 2-ME-induced apoptosis. Our
results thus propose a link between 2-ME, JNK activation,
phosphorylation of Bcl-2 and apoptosis.
3.6. 2-ME also induces apoptosis in hepatic and colon
carcinoma cell lines
To investigate whether the apoptotic e¡ect of 2-ME is more
general and not only limited to breast and prostate carcinoma
cell lines, we included HepG2 (human hepatocarcinoma) and
SW-480 (human colorectal carcinoma) cells in our study. 2-
ME treatment of these cells for 48 h clearly resulted in apo-
ptosis, as shown by DNA fragmentation assays (Fig. 6A).
Again, pretreatment with Ptx inhibited the 2-ME-mediated
e¡ects (Fig. 6A). Furthermore, 2-ME activated SAPK/JNK
in these cells (Fig. 6B) and also caused phosphorylation of
Bcl-2 (Fig. 6C). Therefore, the identi¢ed molecular pathway
for 2-ME-induced apoptosis, i.e. activation of SAPK/JNK
preceding phosphorylation of Bcl-2, was found in several
di¡erent epithelial carcinoma cell lines thus supporting the
notion of a general mechanism of the cellular e¡ects of 2-
ME.
Fig. 3. 2-ME induces activation of SAPK/JNK, which results in caspase-dependent apoptosis. A: Human prostate (PC-3, LNCaP) and breast
(MDA-MB-468, MCF-7) carcinoma cells were treated with 10 WM 2-ME. Cells were collected at the indicated time points, and the activated as
well as total levels of endogenous SAPK/JNK were determined by Western blot analysis. Cells treated with osmotic shock (O-S; 0.5 M NaCl;
30 min) were used as a positive control. B: MDA-MB-468 breast carcinoma cells were treated with 10 WM 2-ME. Cells were collected at the
indicated time points, and the activated as well as total levels of endogenous ERK1/2 were determined by Western blot analysis. Cells treated
with 20% FBS for 30 min were used as a positive control (pos. ctrl.). C: DNA fragmentation analysis from MDA-MB-468 cells treated with
10 WM 2-ME for 24 h in the absence or presence of 10 WM curcumin. D: DNA was extracted from attached and £oating cells in the medium
of the PC-3, LNCaP, MDA-MB-468 and MCF-7 carcinoma cell lines, treated with 2-ME in the presence or absence of 10 WM of a pan-speci¢c
caspase inhibitor (z-VAD-fmk) for the time required to obtain maximal apoptosis, in medium containing 10% FBS. DNA was electrophoresed
in 1.2% agarose gel and visualized by UV light.
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4. Discussion
We report here that 2-ME potently induces apoptosis in
several common carcinoma epithelial cell lines, derived from
prostate, breast, liver and colorectal cancers. Moreover, 2-ME
treatment of rats transplanted with Dunning R3327-PAP
prostate tumors resulted in a reduction of tumor volume,
associated with an increase of the number of apoptotic endo-
thelial and tumor cells. No major toxic side e¡ects of 2-ME
treatment were observed in these in vivo studies. Investiga-
tions of the molecular mechanism by which 2-ME treatment
activates an apoptotic pathway revealed that 2-ME treatment
causes activation of SAPK/JNK and phosphorylation of Bcl-2
that precedes apoptosis.
2-ME potently induced apoptosis of the human prostate
carcinoma cell lines PC-3 and LNCaP, and the human breast
carcinoma cell lines MDA-MB-468 and MCF-7, but with var-
iations in kinetics. The in vivo experiments performed in non-
castrated rats, using the transplantable spontaneous rat pros-
tate Dunning R3327-PAP as a model, showed that 2-ME
treatment could in fact cause tumor regression to half the
size compared to vehicle treatment, after 2 weeks of treat-
ment. Since 2-ME treatment potently inhibits prostate tumor
growth also in vivo, due to its capability to induce apoptosis
of endothelial as well as malignant cells in the tumor without
severe toxic side e¡ects, it is an interesting candidate to im-
prove the therapeutic arsenal in treatment of advanced pros-
tate carcinoma.
2-ME given to the examined tumor cell lines caused a rapid
activation of SAPK/JNK, which was most pronounced in
MDA-MB-468 cells, in accordance with the earlier observed
e¡ect of 2-ME on endothelial cells [14]. 2-ME did not lead to
any ERK1/2 phosphorylation, suggesting a speci¢c activation
of the SAPK/JNK MAPK pathway. Curcumin has been
shown to inhibit SAPK/JNK activation, probably inhibiting
the kinases upstream of SAPK/JNK kinase [39,41]. In the
current study, this drug inhibited 2-ME-induced SAPK/JNK
activation as well as 2-ME-induced apoptosis in MDA-MB-
468 cells, suggesting an involvement of SAPK/JNK activation
in these processes. Most likely caspases are activated after
treatment with 2-ME, since a pan-speci¢c caspase inhibitor
could prevent 2-ME-induced apoptosis. However, we were
not able to detect any expression of the active forms of cas-
pase 1, 3 or 8, by Western blot analysis of lysates from 2-ME-
treated cells (data not shown).
In our e¡ort to further characterize the molecular mecha-
nisms by which 2-ME could induce apoptosis in epithelial-
derived tumor cells, we tested a possible role of GPCRs, by
using Ptx, which speci¢cally inhibits Gi and Go proteins [40].
Ptx decreased the 2-ME-induced activation of SAPK/JNK, as
well as the 2-ME-induced apoptosis of MDA-MB-468 cells in
a dose-dependent manner. Furthermore, the cellular levels of
cAMP have been reported to decrease when Gi proteins are
activated [40] and we found that forskolin, which increases
cAMP levels [42], prevented the 2-ME-induced apoptosis of
MDA-MB-468 cells, suggesting that 2-ME activates a putative
GPCR (data not shown). In fact, 2-ME treatment has earlier
been reported to decrease the cAMP levels in MCF-7 cells
[13]. There are also other reports of non-nuclear actions of
steroids, including that estradiol-17L can potentiate kainate-
induced current in neurons and attenuate the EGF-mediated
Erk-1/2 activity in breast carcinoma cells, probably by activat-
ing a GPCR [43,44]. The apoptosis induced by 2-ME is not
likely to be mediated by the classical estrogen receptor, since
MDA-MB-468 cells, which do not express estrogen receptor-
K, responded well to 2-ME. In addition, the observed rapid 2-
ME-induced activation of SAPK/JNK that we observed in
MDA-MB-468 cells is unlikely to be mediated by transcrip-
tional activity of nuclear estrogen receptors. Moreover, pre-
vious studies have shown that 2-ME has little or no binding
a⁄nity for the classical estrogen receptor and 2-ME lacks
estrogenic activity in the uterus [45,46]. In a recent report
by La Vallee et al., 2-ME was shown to inhibit proliferation
and to induce apoptosis clearly independently of the estrogen
receptors K or L [23]. Recently, it has been reported that
estrogens have rapid modulatory e¡ects on activation of
Erk-1/2, initiated by EGF and activation of JNK induced
by taxol or UV [44,47,48]. These e¡ects of estrogens have
been suggested to occur via putative receptors in the plasma
membrane. Moreover, activation of JNK by natural and syn-
thetic estrogens has been demonstrated [49]. These reports
suggest that estrogens could have e¡ects on alternative mem-
brane-bound receptors. Further studies are needed to deter-
mine the molecular mechanism for the observed activation of
SAPK/JNK by 2-ME.
We report here that 2-ME does not induce apoptosis in
normal mammary cells, suggesting a speci¢c apoptotic e¡ect
of 2-ME on rapidly growing tumor cells, in line with the
recent report from Huang et al., that 2-ME selectively kills
human leukemia cells but not normal lymphocytes [22]. Inter-
Fig. 4. 2-ME-mediated activation of SAPK/JNK and induction of
apoptosis are mediated by GPCR activation. A: MDA-MB-468 cells
were pretreated with increasing concentrations of Ptx for 12 h and
then challenged with 10 WM 2-ME for 1 h. Cells were collected and
the levels of phosphorylated endogenous SAPK/JNK were deter-
mined by Western blot analysis. Cells treated with osmotic shock
(O-S; 0.5 M NaCl, 30 min) were used as a positive control. The lev-
els of total SAPK/JNK were determined as a control for equal load-
ing. B: DNA was extracted from attached cells and cells £oating in
the medium of the MDA-MB-468 cells. The cell lines had been
treated with 10 WM 2-ME for 24 h in the absence or presence of
Ptx at increasing concentrations in medium containing 10% FBS.
DNA was electrophoresed in 1.2% agarose gel and visualized by
UV light.
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estingly, 2-ME was shown to inhibit the transcription of the
superoxide dismutase (SOD) enzymes, which protects cells
from damage induced by superoxide radicals and inhibition
of SOD activity, resulting in apoptosis. Tumor cells are more
dependent on SOD than normal cells, since tumor cells have
higher superoxide production but lower levels of SOD than
normal cells [22]. The reported e¡ect of 2-ME on regulation of
SOD might be correlated with our ¢nding of the selective
induction of apoptosis by 2-ME only in tumor cells. It is
important to note that all observed e¡ects of 2-ME in the
current study were caused by pharmacological concentrations.
However, since no serious side e¡ects of 2-ME treatment were
observed in the animal experiments, a therapeutic use of 2-
ME may be possible.
Bcl-2 belongs to a family of proteins, the members of which
all regulate apoptosis and function as molecular determinators
of cell survival [50^52]. Over-expression of Bcl-2 is associated
with many types of cancers including breast and prostate car-
cinomas [53,54]. The role of Bcl-2 phosphorylation in regula-
tion of apoptosis is unclear, since some studies show poten-
tiation of its anti-apoptotic function, while other studies show
inactivation of its anti-apoptotic function [55^57]. Bcl-2 has
Fig. 6. The 2-ME-induced apoptosis in human liver and colorectal carcinoma cell lines is mediated by GPCR and SAPK/JNK activation, caus-
ing phosphorylation of Bcl-2. A: DNA was extracted from attached cells as well as from cells £oating in the medium of the human liver
(HepG2) and colorectal (SW-480) carcinoma cell lines. The cell lines were treated with 2-ME in the presence or absence of Ptx for 48 h in me-
dium containing 10% FBS. DNA was electrophoresed in 1.2% agarose gel and visualized by UV light. B: HepG2 and SW-480 cells were
treated with 10 WM 2-ME. The cells were collected at the indicated time points and the levels of phosphorylated endogenous SAPK/JNK were
determined by Western blot analysis. Cells treated with osmotic shock (O-S; 0.5 M NaCl, 30 min) were used as a positive control. The level of
total endogenous SAPK/JNK was determined as a control for equal loading. C: HepG2 and SW-480 cells were treated with 10 WM 2-ME for
48 h. Cells were collected and the expression of Bcl-2 was determined by Western blot analysis. Phosphorylated Bcl-2 was recognized as a slow-
er-migrating band as indicated by an arrow.
6
Fig. 5. 2-ME-induced Bcl-2 phosphorylation in human prostate carcinoma cell lines is necessary for induction of apoptosis. A: PC-3, LNCaP,
MDA-MB-468 and MCF-7 cells were treated with 10 WM 2-ME. The cells were collected at the indicated time points and the expression of
Bcl-2 was determined by Western blot analysis. Phosphorylated Bcl-2 was recognized as a slower-migrating band. B: PC-3, DU-145 and
LNCaP cells were treated with 10 WM 2-ME. The cells were collected at the indicated time points and the expression of Bcl-2 was determined
by Western blot analysis. Phosphorylated Bcl-2 was recognized as a slower-migrating band. The same ¢lter was reprobed with actin antibodies
to show that equal amounts of proteins were loaded. C: DU-145 cells were treated with 10 WM 2-ME for indicated times. The cells were col-
lected at the indicated time points and the phosphorylated SAPK/JNK and total SAPK/JNK levels were determined by Western blot analysis.
D: DNA was extracted from attached cells as well as from cells £oating in the medium of the DU-145 prostate carcinoma cell lines, treated
with 2-ME or TGF-L1 for indicated time periods. DNA was electrophoresed in 1.2% agarose gel and visualized by UV light. E: MDA-MB-
468 carcinoma cells were treated with 10 WM 2-ME for 24 h in the absence or presence of Ptx (10 ng/ml), 10 WM curcumin and 10 WM
z-VAD-fmk, then cells were collected and the expression of Bcl-2 was determined by Western blot analysis. Phosphorylated Bcl-2 was recog-
nized as a slower-migrating band and is indicated by an arrow.
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been shown to be phosphorylated during apoptosis induced
by other microtubule-a¡ecting drugs like paclitaxel, which has
similar stabilizing e¡ects on the microtubule system as re-
ported for 2-ME. Treatment with paclitaxel can activate
ERK and SAPK/JNK in MCF-7 breast carcinoma cells,
and in both breast and prostate carcinoma cells, paclitaxel
treatment causes phosphorylation and inactivation of Bcl-2,
leading to apoptosis [58^60]. When the SAPK/JNK pathway
was blocked, no phosphorylation of Bcl-2 occurred and cells
were rescued from apoptosis [60], indicating that Bcl-2 is
phosphorylated, directly or indirectly by SAPK/JNK [61,62].
Furthermore, 2-ME treatment of a erythromyeloid leukemia
cell line (K562) has been reported to activate SAPK/JNK and
cause phosphorylation of Bcl-2 [63]. Filippovich et al. [64]
showed that radiation-induced apoptosis of human myeloma
cells is preceded by Bcl-2 phosphorylation. The present study
shows that 2-ME treatment also results in SAPK/JNK activa-
tion and phosphorylation of Bcl-2 in all investigated epithelial
carcinoma cell lines that responded with apoptosis. We dem-
onstrated that Ptx treatment prevented the 2-ME-induced
phosphorylation of Bcl-2 and concomitant apoptosis of cells
suggesting that 2-ME activates the SAPK/JNK pathway.
When curcumin was used, the 2-ME-induced phosphorylation
of Bcl-2 was prevented, supporting the notion that activation
of SAPK/JNK is associated with the phosphorylation of Bcl-
2. Interestingly, MacCarthy-Morrogh et al. [65] recently re-
ported that a derivative of 2-ME resulted in increased phos-
phorylation of Bcl-2 and apoptosis of human mammalian cell
lines in vitro, when compared to the e¡ects of the parent 2-
ME. Our ¢nding that 2-ME treatment of DU-145 prostate
carcinoma cells, which lack Bcl-2 expression, causes SAPK/
JNK activation but not apoptosis suggests that Bcl-2 expres-
sion is important for 2-ME-induced apoptosis in carcinoma
cells and the presence of Bcl-2 could therefore be necessary for
e⁄cient treatment of patients with 2-ME. Also in the human
hepatocarcinoma and colorectal carcinoma cell lines (HepG2,
SW-480), 2-ME treatment resulted in an activation of SAPK/
JNK and in phosphorylation of Bcl-2, which preceded apo-
ptosis. Our data suggest that 2-ME causes activation of the
SAPK/JNK pathway, which leads to phosphorylation of Bcl-2
and apoptosis in several investigated cell lines derived from
breast, prostate, liver and colorectal carcinomas. Further-
more, treatment with 2-ME inhibited prostate tumor growth
in vivo by causing apoptosis in tumor and endothelial cells,
without any apparent major side e¡ects on the animals. Since
2-ME inhibits angiogenesis, lacks estrogenic activity and
shows minimal toxicity in vivo, while it has potent cytotoxic
e¡ects on several common epithelial tumor cells, it is an at-
tractive candidate for future clinical trials for prevention or
treatment of carcinomas.
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